A Struggling Reputation: How ProPhase Labs Plans to Rebound with a Promising Cancer Test
ProPhase Labs faces financial challenges with its stock price below $1, risking NASDAQ delisting. The company aims to improve liquidity by collecting $50 million in accounts receivable and potentially selling…